The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The initial consideration for the transaction is US$ 12 million
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Subscribe To Our Newsletter & Stay Updated
